Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11490233 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD);   Drug: Doxazosin 4 mg every day (QD)

Indicates status has not been verified in more than two years